Pasar al contenido principal

ANALISIS TRANSCRIPCIONAL Y MODULACION FUNCIONAL DE CIRCUITOS NEURONALES DE MEMORIA EN LA ENFERMEDAD DE ALZHEIMER

PID2022-137668OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synaptic vulnerability to amyloid-β and tau pathologies differentially disrupts emotional and memory neural circuits

  • Capilla López, Maria Dolores|||0000-0002-9483-4887
  • Deprada Fernández, Ángel|||0000-0002-7860-6307
  • Andrade-Talavera, Yuniesky|||0000-0002-5295-0169
  • Martínez Gallego, Irene|||0000-0002-8936-8201
  • Coatl-Cuaya, Heriberto|||0000-0003-4953-6562
  • Sotillo Sotillo, Paula
  • Rodríguez Álvarez, José|||0000-0001-8582-8082
  • Rodríguez Moreno, Antonio|||0000-0002-8078-6175
  • Parra-Damas, Arnaldo|||0000-0001-5683-060X
  • Saura Antolín, Carlos|||0000-0003-3692-5657
Alzheimer's disease (AD) is characterized by memory loss and neuropsychiatric symptoms associated with cerebral amyloid-β (Aβ) and tau pathologies, but whether and how these factors differentially disrupt neural circuits remains unclear. Here, we investigated the vulnerability of memory and emotional circuits to Aβ and tau pathologies in mice expressing mutant human amyloid precursor protein (APP), Tau or both APP/Tau in excitatory neurons. APP/Tau mice develop age- and sex-dependent Aβ and phosphorylated tau pathologies, the latter exacerbated at early stages, in vulnerable brain regions. Early memory deficits were associated with hippocampal tau pathology in Tau and APP/Tau mice, whereas anxiety and fear appeared linked to intracellular Aβ in the basolateral amygdala (BLA) of APP and APP/Tau mice. Transcriptome hippocampal profiling revealed gene changes affecting myelination and RNA processing in Tau mice, and inflammation and synaptic-related pathways in APP/Tau mice at 6 months. At 9 months, we detected common and region-specific changes in astrocytic, microglia and 63 AD-associated genes in the hippocampus and BLA of APP/Tau mice. Spatial learning deficits were associated with synaptic tau accumulation and synapse disruption in the hippocampus of Tau and APP/Tau mice, whereas emotional disturbances were linked to Aβ pathology but not synaptic tau in the BLA. Interestingly, Aβ and tau exhibited synergistic detrimental effects in long-term potentiation (LTP) in the hippocampus but they counteract with each other to mitigate LTP impairments in the amygdala. These findings indicate that Aβ and tau pathologies cause region-specific effects and synergize to induce synaptic dysfunction and immune responses, contributing to the differing vulnerability of memory and emotional neural circuits in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HEBE, A novel chimeric chronokine for ameliorating memory deficits in Alzheimer's disease

  • Esandi Jauregui, Jon|||0000-0001-5529-2686
  • Renault de Barros, Pedro Victor|||0000-0002-5649-3057
  • Capilla López, Maria Dolores|||0000-0002-9483-4887
  • Blanch Garcia, Rebeca|||0000-0001-6726-4084
  • Edo Salvador, Ángel
  • Ramirez-Gómez, David
  • Bosch i Merino, Assumpció|||0000-0002-7205-2796
  • Almolda Ardid, Beatriz|||0000-0001-6631-4385
  • Saura, Carlos Alberto
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by amyloid-β and Tau protein depositions, with treatments focusing on single proteins have shown limited success due to the complexity of pathways involved. This study explored the potential of chronokines -proteins that modulate aging-related processes- as an alternative therapeutic approach. Specifically, we focused on a novel pleiotropic chimeric protein named HEBE, combining s-KL, sTREM2 and TIMP2, guided by bioinformatic analyses to ensure the preservation of each protein's conformation, crucial for their functions. In vitro studies confirmed HEBE's stability and enzymatic activities, even suggesting it has different activities compared to the individual chronokines. In vivo experiments on APP/Tau mice revealed improved learning and memory functions with HEBE treatment, along with decreased levels of phosphorylated Tau and minor effects on amyloid-β levels. These findings suggest that HEBE is as a promising therapeutic candidate for ameliorating memory deficits and reducing pTau in an AD mouse model.